What severe adverse events and hospitalizations have been documented from veterinary ivermectin ingestion in people?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Veterinary ivermectin ingestion in people has been repeatedly linked to severe neurologic toxicity — including altered mental status, ataxia, seizures, coma — and to a substantial rate of emergency visits and hospitalizations in case series and regulatory summaries [1] [2] [3]. Published reports include ICU admissions and at least one death associated with non‑standard routes or high doses of veterinary product, while regulators warn of additional serious events such as hypotension, severe skin reactions, and liver injury [4] [5] [2] [6].
1. Hospitalizations, emergency visits and mortality recorded in case series
A multi‑case review identified 37 patients with ivermectin toxicity collected from clinical reports, of whom the majority required acute care: 21 were hospitalized and 13 treated in emergency departments, with three managed as outpatients and one recorded death in that cohort [1]. Separate surveillance and case reports from U.S. clinicians likewise documented multiple hospitalizations among people who used veterinary formulations for COVID‑19 prevention or treatment, with six of 21 reported patients admitted for toxic effects in one NEJM summary [2].
2. Predominant clinical syndrome: neurotoxicity and altered mental status
Neurotoxicity was the dominant clinical effect across series, appearing in roughly 30 of the 37 patients in the OHSU review and manifesting as altered mental status, lethargy, somnolence, tremor, incoordination and seizures [1] [7]. Case reports emphasize severe presentations: an ICU admission for “severe neurotoxicity” after intravenous administration of veterinary ivermectin measured a toxic serum concentration and required intensive care support [5] [4].
3. Other organ systems: gastrointestinal, cardiovascular, dermatologic and hepatic events
Beyond neurologic findings, documented adverse events included gastrointestinal symptoms such as nausea, vomiting and diarrhea and musculoskeletal complaints; regulatory and extension materials also list potential for sudden drops in blood pressure, severe skin rashes necessitating hospitalization, facial or limb swelling, and liver enzyme abnormalities or hepatitis linked to ivermectin exposure [1] [6] [2]. The NEJM report summarized a spectrum of non‑neurologic toxicities among people who obtained veterinary products, though most hospitalizations were driven by neurologic concerns [2].
4. Dose, formulation and route matter: veterinary products, higher doses, and intravenous use
Reports consistently tie worse outcomes to veterinary formulations and to doses well above human therapeutic ranges: patients taking veterinary ivermectin often ingested large single doses or repeated high doses and had higher rates of altered mental status compared with those taking prescription tablets [1]. In the documented case of intravenous veterinary ivermectin administration, the atypical parenteral route and combined high oral dosing produced severe, measurable neurotoxicity — an outcome the authors flagged as especially dangerous because veterinary products are not intended or tested for human use [4] [5].
5. Mechanisms and susceptibility: blood‑brain barrier, P‑glycoprotein and comorbid risks
Biological plausibility for central nervous system toxicity rests on ivermectin’s action on GABAergic and glutamate‑gated chloride channels and on variable penetration of the blood‑brain barrier controlled by P‑glycoprotein transporters; genetic or disease‑related reductions in P‑glycoprotein can increase brain concentrations and have been implicated in serious neurologic events seen with off‑label high dosing or veterinary preparations [7]. Authors and regulatory bodies also note that higher cumulative exposure and certain coexisting infections or drug interactions may increase risk, though the relative contribution of each factor varies across reports [7] [8].
6. Public health context, reporting limits and conclusion
Clinical series and regulatory summaries converge on a clear finding: use of veterinary ivermectin by humans — especially at high doses or by non‑oral/experimental routes — has produced serious adverse events and prompted emergency care and hospital admission, including ICU care and at least one fatality in reported series [1] [2] [4]. However, available publications are case series, case reports and surveillance summaries that cannot quantify population‑level incidence or definitively separate the roles of dose, route, formulation, comorbidities or concomitant drugs; the literature therefore documents clear harms in identified cases but cannot by itself produce precise risk estimates for all users of veterinary formulations [1] [8].